Serum IgG and Renal Transplantation

Ku, G. De la Cruz; Varghese, Z.; Fernando, O. N.; Baillod, Rosemarie; Hopewell, J. P.; Moorheàd, J. F.

doi:10.1136/bmj.4.5894.702

Cited by 12 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The meta‐analysis included 1756 patients (18 studies) . Characteristics of the studies included in the analysis are presented in Table .…”

Section: Resultsmentioning

confidence: 99%

“…Severe HGG seems to have a more significant impact on all‐cause mortality compared with overall HGG; probably this could be explained by the increased risk of different infections with severe HGG. It has been previously reported that infections represent the number one cause of morbidity and mortality in SOT recipients . HGG may indirectly raise mortality by increasing the risk of various infections.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

What Is the Impact of Hypogammaglobulinemia on the Rate of Infections and Survival in Solid Organ Transplantation? A Meta-Analysis

Florescu

Kalil

Qiu

et al. 2013

American Journal of Transplantation

143

145

View full text Add to dashboard Cite

Hypogammaglobulinemia has been described after solid organ transplantation and has been associated with increased risk of infections. The aim of the study was to evaluate the rate of severe hypogammaglobulinemia and its relationship with the risk of infections during the first year posttransplantation. Eighteen studies (1756 patients) that evaluated hypogammaglobulinemia and posttransplant infections were included. The data were pooled using the DerSimonian and Laird random-effects model. Q statistic method was used to assess statistical heterogeneity. Within the first year posttransplantation, the rate of hypogammaglobulinemia (IgG < 700 mg/dL) was 45% (95% CI: 0.34-0.55; Q ¼ 330.1, p < 0.0001), the rate of mild hypogammaglobulinemia (IgG ¼ 400-700 mg/dL) was 39% (95% CI: 0.22-0.56; Q ¼ 210.09, p < 0.0001) and the rate of severe hypogammaglobulinemia (IgG < 400 mg/dL) was 15% (95% CI: 0.08-0.22; Q ¼ 50.15, p < 0.0001).

show abstract

“…The meta‐analysis included 1756 patients (18 studies) . Characteristics of the studies included in the analysis are presented in Table .…”

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

What Is the Impact of Hypogammaglobulinemia on the Rate of Infections and Survival in Solid Organ Transplantation? A Meta-Analysis

Florescu

Kalil

Qiu

et al. 2013

American Journal of Transplantation

143

145

View full text Add to dashboard Cite

show abstract

“…In comparison, the renal allograft recipients showed a significant reduction in IgG and IgA levels. A reduced IgG has been found in renal transplant patients [18,24] shown to be due to a lower mean rate of IgG synthesis [49].…”

Section: Discussionmentioning

confidence: 99%

Defective Immune and Phagocytic Functions in Uraemia and Renal Transplantation

McIntosh

Hansen

Ziegler

et al. 1976

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The humoral, cellular and neutrophil responses of uraemic patients maintained by haemodialysis were compared with those of renal transplant recipients. Humoral immunity was reduced only in the transplant group. Cell-mediated immunity was abnormal in both groups but more decreased in the transplant group studied particularly within 3 months of transplantation. The neutrophil bactericidal capacities were defective in both groups. Infectious complications were often associated with defective cellular immunity, but fatal infections occurred only in transplant patients over 40 years of age with combined cellular and neutrophil defects. No single test was predictive of graft survival in uraemic patients. The depressed cellular immune responses in uraemia, of the degree seen in the immunosuppressed transplant recipient, may explain the better prognosis of renal transplants compared with other organ transplants.

show abstract

“… Impact of selected primary and secondary antibody deficiencies on IgG. E5 , E6 , E7 , E8 , E9 , E10 , E11 , E12 , E13 , E14 , E15 , E16 , E17 , E18 , E19 , E20 , E21 , E22 , E23 , E24 , E25 , E26 , E27 , E28 , E29 , E30 , E31 , E32 , E33 , E34 , E35 , E36 , E37 , E38 , E39 , E40 , E41 , E42 , E43 , E44 , E45 , E46 , E47 , E48 , E49 , E50 , E51 , E52 , E53 , E54 , E55 , E56 , E57 , E58 , E59 , E60 , E61 , E62 , E63 , E64 , E65 , E66 , E67 ...…”

Section: Appendixunclassified

Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations

Peter

Ochs

Cunningham‐Rundles

et al. 2020

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

The neonatal fragment crystallizable (Fc) receptor (FcRn) functions as a recycling mechanism to prevent degradation and extend the half-life of IgG and albumin in the circulation. Several FcRn inhibitors selectively targeting IgG recycling are now moving rapidly toward clinical practice in neurology and hematology. These molecules accelerate the destruction of IgG, reducing pathogenic IgG and IgG immune complexes, with no anticipated effects on IgA, IgM, IgE, complement, plasma cells, B cells, or other cells of the innate or adaptive immune systems. FcRn inhibitors have potential for future use in a much wider variety of antibody-mediated autoimmune diseases. Given the imminent clinical use, potential for broader utility, and novel mechanism of action of FcRn inhibitors, here we review data from 4 main sources: (a) currently available activity, safety, and mechanism-of-action data from clinical trials of FcRn inhibitors; (b) other procedures and treatments that also remove IgG (plasma donation, plasma exchange, immunoadsorption); (c) diseases resulting in loss of IgG; and (d) primary immunodeficiencies with potential mechanistic similarities to those induced by FcRn inhibitors. These data have been evaluated to provide practical considerations for the assessment, monitoring, and reduction of any potential infection risk associated with FcRn inhibition, in addition to highlighting areas for future research.

show abstract

Serum IgG and Renal Transplantation

Cited by 12 publications

References 10 publications

What Is the Impact of Hypogammaglobulinemia on the Rate of Infections and Survival in Solid Organ Transplantation? A Meta-Analysis

What Is the Impact of Hypogammaglobulinemia on the Rate of Infections and Survival in Solid Organ Transplantation? A Meta-Analysis

Defective Immune and Phagocytic Functions in Uraemia and Renal Transplantation

Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations

Contact Info

Product

Resources

About